• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Profound Medical Corp.

    9/12/24 6:02:56 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care
    Get the next $PROF alert in real time by email
    S-8 1 tm2423332d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on September 12, 2024

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    PROFOUND MEDICAL CORP.

    (Exact Name of Registrant as Specified in its Charter)

     

    Ontario, Canada       Not Applicable
    (State or other jurisdiction of
    incorporation or organization)
          (IRS Employer
    Identification No.)

     

    2400 Skymark Avenue,
    Unit 6, Mississauga,
    Ontario L4W 5K5
    (647) 476-1350

    (Address of Principal Executive Offices)(Zip Code)

     

    Profound Medical Corp. Long Term Incentive Plan

    Profound Medical Corp. Amended and Restated Share Option Plan

    (Full Title of the Plans)

     

    Profound Medical (U.S.) Inc.
    9160 Forum Corporate Parkway, Suite 359
    Fort Myers, Florida
    33905

    (Name and Address of Agent for Service)

     

    (647) 476-1350

    (Telephone Number, Including Area Code, of Agent for Service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer  ¨   Accelerated filer ¨
    Non-accelerated filer x   Smaller reporting company  ¨
        Emerging growth company  x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.    ☐

     

     

     

     

     

     

    Explanatory Note

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 2,615,048 common shares of Profound Medical Corp. (the “Registrant”) that may be issued pursuant to the Registrant’s Amended and Restated Share Option Plan or Long Term Incentive Plan (together, the “Plans”). The Registrant previously registered 2,649,660 common shares for issuance under the Plans pursuant to Registration Statements on Form S-8 filed with the Securities and Exchange Commission on November 7, 2019 (File No. 333-234574) and May 20, 2020 (File No. 333-238528). Pursuant to General Instruction E to Form S-8, the contents of such Registration Statements on Form S-8 are hereby incorporated by reference herein, except to the extent supplemented or amended or superseded by the information set forth herein.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.Exhibits.

     

    The following documents are filed as exhibits to this Registration Statement.

     

    Exhibit No.   Description of Exhibit
    4.1   Articles of Incorporation (incorporated by reference to Exhibit 4.1 to the Registrant’s Form S-8 filed with the Commission on November 7, 2019).
    4.2   Articles of Amendment (incorporated by reference to Exhibit 4.2 to the Registrant’s Form S-8 filed with the Commission on November 7, 2019).
    4.3   Articles of Amalgamation (incorporated by reference to Exhibit 4.3 to the Registrant’s Form S-8 filed with the Commission on November 7, 2019).
    4.4   Bylaws (incorporated by reference to Exhibit 4.4 to the Registrant’s Form S-8 filed with the Commission on November 7, 2019).
    5.1*   Opinion of Mintz LLP
    23.1*   Consent of Mintz LLP (included in Exhibit 5.1).
    23.2*   Consent of PricewaterhouseCoopers LLP.
    24.1*   Power of Attorney (included in the signature page to this Registration Statement).
    107*   Filing Fee Table.

     

    * Filed herewith.

     

     

     

     

    Item 9.Undertakings.

     

    (a)The undersigned Registrant hereby undertakes:

     

    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the “Securities Act”);

     

    (ii)To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and

     

    (iii)To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mississauga, Province of Ontario, Canada on September 12, 2024.

     

      PROFOUND MEDICAL CORP.
       
      By: /s/ Rashed Dewan
        Name: Rashed Dewan
        Title: Chief Financial Officer

     

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Arun Menawat and Rashed Dewan, and each of them, with full power to act without the other, his or her true and lawful attorneys-in-fact and agents, with full and several power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post effective amendments, and supplements to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or his or her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities indicated on September 12, 2024.

     

    Signature   Title
         
    /s/ Arun Menawat   Chief Executive Officer and Chairman (Principal Executive Officer)
    Arun Menawat  
         
    /s/ Rashed Dewan   Rashed Dewan (Principal Financial Officer and Principal Accounting Officer)
    Rashed Dewan  
         
    /s/ Kris Shah   Director
    Kris Shah  
         
    /s/ Arthur Rosenthal   Director
    Arthur Rosenthal  
         
    /s/ Brian Ellacott   Director
    Brian Ellacott  
         
    /s/ Cynthia Lavoie   Director
    Cynthia Lavoie  
         
    /s/ Murielle Lortie   Director
    Murielle Lortie  

     

     

     

     

    AUTHORIZED REPRESENTATIVE

     

    Pursuant to the requirements of the Securities Act of 1933, the undersigned certifies that it is the duly authorized United States representative of the Registrant and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mississauga, Province of Ontario, Canada, on September 12, 2024.

     

      PROFOUND MEDICAL CORP.
      (Authorized Representative in the United States)
       
      By: /s/ Arun Menawat
        Name: Arun Menawat
        Title: Chief Executive Officer and Chairman

     

     

     

    Get the next $PROF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PROF

    DatePrice TargetRatingAnalyst
    7/23/2024$16.50Buy
    Lake Street
    7/16/2024$9.00 → $12.00Hold → Buy
    Stifel
    11/28/2023$11.00Hold
    Stifel
    8/4/2023$20.00 → $200.00Strong Buy → Outperform
    Raymond James
    3/21/2023$5.50 → $10.00Buy → Hold
    Jefferies
    3/7/2022$28.00 → $14.00Outperform
    Cowen & Co.
    2/22/2022$28.00 → $23.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $PROF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Menawat Arun Swarup bought $100,151 worth of shares (22,030 units at $4.55), increasing direct ownership by 4% to 587,089 units (SEC Form 4)

    4 - Profound Medical Corp. (0001628808) (Issuer)

    5/20/25 1:56:42 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women's Health

    TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that PRO FAMILIA Specialist Hospital in Rzeszów, Poland has completed its 500th Sonalleve® Procedure. The MRI-guided therapy provides women with a non-surgical alternative for treating common gynecologic conditions—delivering targeted relief with no incisions, no blood loss during the procedure, no overnight hospital stay, and a faster recovery. "Sonalleve is giving more women access to a safer, gentler a

    2/5/26 8:00:00 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Announces Upcoming Investor Events

    TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce its participation in the following investor events in February. Lake Street Life-Sciences Invitational: Profound is scheduled to participate in a series of one-on-one meetings February 4th-5th in Scottsdale, AZ.BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference: The Company is scheduled to participate in a series of one-on-one meetings February 10th-11th in Snowbir

    1/27/26 4:30:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®

    Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for 2025-26 TORONTO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce the world-renowned Mount Sinai Hospital has successfully treated its first prostate cancer patient with the TULSA-PRO® system. The TULSA Procedure™ represents a major advancement in pr

    1/15/26 7:30:00 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    SEC Filings

    View All

    Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Profound Medical Corp. (0001628808) (Filer)

    2/5/26 8:05:28 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Profound Medical Corp. (0001628808) (Filer)

    1/27/26 6:17:25 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Profound Medical Corp. (0001628808) (Filer)

    1/15/26 7:35:27 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Menawat Arun Swarup bought $100,151 worth of shares (22,030 units at $4.55), increasing direct ownership by 4% to 587,089 units (SEC Form 4)

    4 - Profound Medical Corp. (0001628808) (Issuer)

    5/20/25 1:56:42 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Profound Medical with a new price target

    Lake Street initiated coverage of Profound Medical with a rating of Buy and set a new price target of $16.50

    7/23/24 8:51:59 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical upgraded by Stifel with a new price target

    Stifel upgraded Profound Medical from Hold to Buy and set a new price target of $12.00 from $9.00 previously

    7/16/24 7:45:31 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Profound Medical with a new price target

    Stifel initiated coverage of Profound Medical with a rating of Hold and set a new price target of $11.00

    11/28/23 7:53:24 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Leadership Updates

    Live Leadership Updates

    View All

    Profound Medical Annual General and Special Meeting of Shareholders Voting Results

    TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 4, 2025 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders

    5/14/25 4:45:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

    – Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of Tom Tamberrino as its new Chief Commercial Officer. Abbey Goodman, the Company's current CCO, will t

    10/16/24 4:15:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Annual General Meeting of Shareholders Voting Results

    TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Comp

    5/15/24 5:00:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Financials

    Live finance-specific insights

    View All

    Profound Medical Reports Strong Third Quarter 2025 Financial Results

    TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the third quarter ended September 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).   Business Highlights Revenue grew 87% year-over-year to a record $5.3 million in the third quarter of 2025.Gross margin increased 1,119 basis p

    11/13/25 4:05:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

    TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the third quarter of 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars. For the quarter ended September 30, 2025, Profound anticipates total revenues to be in the approximate range of $5.2 million to $5.3 million, representing revenue growth of between 84% and 87% over $2.8 million in the same three-month period a year ag

    10/7/25 7:45:00 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Announces Second Quarter 2025 Financial Results

    TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the second quarter ended June 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Utilization of current TULSA-PRO® systems continues to grow, with "same store" procedure volumes up 10% sequentially from Q1-2

    8/14/25 4:05:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.

    SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

    11/14/24 4:27:34 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.

    SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

    8/5/24 7:50:30 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Profound Medical Corp. (Amendment)

    SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

    3/13/24 4:00:16 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care